Clinical Trials Directory

Trials / Completed

CompletedNCT07407257

SBRT for Liver Tumors, Liver Metastases, and Pancreatic Tumors

SBRT of Liver Tumors and Metastases and Pancreatic Tumors

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
65 (actual)
Sponsor
Institute of Oncology Ljubljana · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

This prospective observational study evaluates the safety and effectiveness of stereotactic body radiotherapy (SBRT) for liver tumors, liver metastases, and pancreatic tumors. The study focuses on systematic monitoring and optimization of the SBRT treatment process, including adherence to the implemented protocol, with the aim of simplifying methods while maintaining treatment safety.

Detailed description

Stereotactic body radiotherapy (SBRT) is an advanced radiotherapy technique that enables delivery of high radiation doses to tumors with high precision while limiting exposure of surrounding healthy tissues. This study prospectively follows patients treated with SBRT for primary liver tumors, liver metastases, and pancreatic tumors at the Institute of Oncology Ljubljana. The primary aim is to monitor and optimize all steps of the SBRT workflow, including protocol adherence, in order to ensure safe implementation and to evaluate treatment outcomes. The study also aims to assess whether the established SBRT protocol can be simplified without compromising patient safety. Treatment safety and effectiveness outcomes will be evaluated during follow-up, and the collected data will be used to support further refinement of SBRT procedures for upper gastrointestinal tumors

Conditions

Interventions

TypeNameDescription
RADIATIONStereotactic Body Radiotherapy (SBRT)Stereotactic body radiotherapy (SBRT) delivered according to the institutional protocol for treatment of liver tumors, liver metastases, and pancreatic tumors, with high-dose hypofractionated radiation and image-guided radiotherapy techniques.

Timeline

Start date
2019-01-01
Primary completion
2024-12-31
Completion
2025-12-31
First posted
2026-02-12
Last updated
2026-02-18

Locations

1 site across 1 country: Slovenia

Source: ClinicalTrials.gov record NCT07407257. Inclusion in this directory is not an endorsement.